IMMUTEP LIMITED — Board/Management Information 2010

Aug 18, 2010

==> picture [193 x 52] intentionally omitted <==

ASX/Media Release 19 August 2010

PRIMA BIOMED APPOINTS NEW SENIOR VICE PRESIDENT FOR CVac CLINICAL PROGRAMS

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce the appointment of Dr Sharron Gargosky as Senior Vice President for the Company’s CVac™ Clinical Programs.

Dr Gargosky has 18 years experience in the biotechnology and pharmaceutical industries, and has worked in senior positions for three different companies which have successfully received FDA approval for orphan drugs.

She will be based in United States and will be a key senior member of Prima’s world class executive team. In her new position Dr Gargosky will be responsible for managing the clinical team working on the CVac™ immunotherapy cancer vaccine. This will be a pivotal role within the Company as it embarks on its late stage clinical trials for CVac™.

Prior to joining Prima, Dr Gargosky was a member of Member of ILMU Consulting LLC. In this role she provided project management and operational expertise in the area of pharmaceutical drug and biologic development - from the early research phase through to Phase IV Trials and the FDA approval process.

She has also previously held the positions of; Chief Scientific Officer at Pulse Health LLC in Portland in the USA, Chief Scientific Officer and Senior Vice President of Corporate Development at Hyperion Therapeutics Inc. in San Francisco, and Executive Director of Research and Development at Medicis/Ucyclyd Pharma, Arizona, among other senior roles.

Commenting on Dr Gargosky’s appointment Prima BioMed’s managing director Martin Rogers said: “I am delighted to welcome Dr Gargosky to the Prima team. Her depth of experience and expertise in the development process of new drug candidates particularly Orphan Drug designated candidates, is of an extremely high standard, and will be invaluable as we progress our CVac™ clinical programs.”

Dr Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D. in Biochemistry from University of Adelaide in Australia (in collaboration with CSIRO. Divisions of Human Nutrition, South Australia), First Class Honors in Biochemistry from University of Adelaide, and a Bachelor of Science, Biochemistry (Distinction), Microbiology, Immunology & Virology (Distinction) from University of Adelaide.

ENDS

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889

For further information please contact:

Mr Martin Rogers Chief Executive Officer Prima BioMed Ph: +61 0 428 268 357 E: martin.rogers@primabiomed.com.au W: www.primabiomed.com.au

James Moses Investor and Media Relations Mandate Corporate Ph: +61 0 420 991 574 E: james@mandatecorporate.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed’s lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima’s lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally.

The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889